Clinical TrialJun 18, 2026, 08:42 AM
AVITA Medical's RECELL GO successful in 17 UK burn patients
AI Summary
AVITA Medical announced successful clinical data for its RECELL GO automated system in the U.K., presented at the British Burn Association Annual Meeting. The first U.K. case series involved 17 burn and reconstructive surgery patients, demonstrating successful use, uncomplicated donor-site healing, complete graft take, and improved operating room workflow. This marks an important milestone in the global adoption of RECELL GO, which is CE-marked in Europe and the U.K., and recently authorized in Australia and New Zealand.
Key Highlights
- First U.K. clinical experience of RECELL GO presented at British Burn Association Annual Meeting.
- Case series involved 17 burn and reconstructive surgery patients at Stoke Mandeville Hospital.
- All patients successfully received RECELL Spray-On Skin Cells prepared using RECELL GO.
- Uncomplicated donor-site healing and complete graft take reported for all patients.
- Workflow benefits included reduced procedural variability and improved consistency.
- RECELL GO is CE-marked in Europe/U.K. and authorized in Australia/New Zealand.
- Systematic review of RECELL showed safety/effectiveness in over 8,000 patients globally.
Price Impact
More from RCEL